75 results about "ASPIRIN RESISTANCE" patented technology

The invention discloses a method for detecting the precise medication of four kinds of common clinic cardiovascular medicine and a special primer. The invention provides the special primer for detecting four kinds of medicine-resistant SNP sites of the four kinds of common clinic cardiovascular medicine. The eight-SNP site detection relevant to aspirin resistance, nitroglycerin resistance, warfarin individual difference, clopidogrel resistance is efficiently completed through once experiment; the precise medication gene detection of aspirin, nitroglycerin, warfarin and clopidogrel is completed by once experiment; the experiment cost is reduced. The PCR primer designed according to each SNP site and the unique UEP primer have high specificity. The method has high application values on guiding the clinic precise medication of aspirin, nitroglycerin, warfarin and clopidogrel, and is suitable for popularization and application.

The invention discloses a new use of compound Danshen tablets. The compound Danshen tablets has the advantages of having resistant function of aspirin resisting and improving life quality of patients with cardiovascular disease of aspirin resistance through clinical experiment showing.

A Gene detection kit for detect individualized aspirin use is characterize in that that kit comprises the following components: PTGS1 (-842A) G), ITGA2 (759C) T), ITGB3 (176T) C) and PEAR1 (-9-3996G)site amplification and sequence primer, PCR amplification reagent, PCR product purification reagent and DNA sequencing reagent, that nucleotide sequence of each prim is as follows: SEQ NO. 5-12 as shown in table 1. The invention has the following technical effects: a gene detection kit for individualized aspirin medication of Chinese population is provided, and the sensitivity is high and the accuracy is high. The kit is used for PTGS1 (-842A) G), ITGA2 (759C) T), ITGB3 (176T) C) and PEAR1 (-9-3996G) A) genotyping, which can detect genetic differences between individuals and determine the riskof aspirin resistance in advance, so that individualized antiplatelet therapy can be used to achieve accurate treatment and prevent cardiovascular events.

The invention discloses nucleic acid and a kit used for detecting polymorphism of COX-1, COX-2 and GPIIIa genes as well as detecting method for detecting polymorphism of the COX-1, COX-2 and GPIIIa genes, and the method is strong in specificity, is high in sensitivity, is high in accuracy and is simple to operate. The detected results can provide guidance meaning for aspirin resistance. The detecting method provided by the invention adopts completely closed-tube operation, is simple to operate, is convenient and quick, obtains the detected results by directly detecting a fluorescence signal value in a PCR process, PCR post-treatment or electrophoresis detection is not needed, the problems such as easy pollution and false positive results in the conventional PCR technology are overcome, the nonspecific amplification problem can be effectively avoided, and therefore, the nucleic acid, the kit and the method are suitable for large-scale sample detection.

The invention belongs to the technical field of biomedicine and relates to a chemiluminiscence detection kit for detecting the metabolism of aspirin and the high reactivity of platelets and a detection method. The kit comprises an 11-dehydro-thromboxane B2 monoclonal antibody, an 11-dehydro-thromboxane B2 competitive product, magnetic particles and a luminous substrate; and whether a patient has drug resistance or resistance to aspirin can be detected through the detection kit. The detection method has the advantages of high sensitivity, high accuracy and little possibility of being influencedby biochemical indexes. The detection method provides a scientific reference basis for clinical administration and can be applied to clinical medication guidance. With the detection method adopted, the problem of the failure or poor effect of the antiplatelet aggregation treatment of a clinical patient caused by aspirin resistance of the clinical patient can be solved.

A Chinese medicine for treating the aspirin-resistant cardiovascular disease is prepared from red sage root, Chuanxiong rhizome and kudzu vine root.

An application of red sage root and its extract in preparing the medicines in the form of dripping pill or tablet for treating the aspirin-resistant cardiovascular and cerebrovascular diseases is disclosed.

The invention eblogns to the technical field of biology and specifically relates to a human phlebothrombosis risk gene F5 and PAI-1 polymorphism detection kit as well as a preparation method and application thereof. The kit is prepared from a detection reagent, a positive control product and a negative control product, wherein the detection reagent is used for amplifying gene F5 and PAI-1 polymorphism related to the human phlebothrombosis risk, wherein the detection reagent applied to the F5 gene polymorphism is prepared from a primer sequence, a PNA sequence and PCR reaction liquid; the primer sequence is used for amplifying an rs6025 site of F5 gene; the detection reagent applied to the PAI-1 gene polymorphism is prepared from a primer sequence, a PNA sequence and PCR reaction liquid; the primer sequence is used for amplifying an rs17999762 site of the PAI-1 gene. The kit disclosed by the invention is used for detecting the human aspirin resistance gene polymorphism and has the advantages of high flexibility, high specificity, convenience in operation, reliable results and the like; furthermore, detection can be finished within 1 hour, and result reading is simple and objective.

The invention discloses application of a salviae miltiorrhizae and flos carthami composition to enhancement of the antithrombotic function of aspirin. On the basis of the traditional Chinese medicine prescription compatibility theory and a large number of experiments and researches, the salviae miltiorrhizae and flos carthami composition is screened out and can remarkably inhibit the esterase activity of aspirin, the hydrolysis speed of aspirin is reduced, the acting time of aspirin is prolonged, aspirin resistance is inhibited, the antiplatelet function of aspirin is enhanced, the antithrombotic treatment effect can be enhanced by clinically using the salviae miltiorrhizae and flos carthami composition and aspirin, adverse effects are reduced, and application prospects are important.

The invention relates to the application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance wherein the composition comprises (by weightg ratio) Chinese angelica root 10-100mg, astragalus root 50-100mg, red peony root 10-50g, Ligusticum wallichii 20-100g, radix salvia miltiorrhiza 60-300g, cassia twig 10-100g, peach kernel 10-100g, safflower 10-100g, mulberry twigs 10-200g, achyranthes and cyathula root 10-200g, frankincense 10-150g, myrrh 10-150g, hooked uncaria 10-200g, earthworm 10-500g, buthus martensi kirsch 10-1000g, centipede 1-100 pieces, spatholobus stem 10-500g, leech 10-1000g.

The invention discloses a detection kit for detecting the metabolic capability of aspirin and a preparation method of the detection kit, and the kit comprises an elisa plate coated with a monoclonal antibody of 11-dehydrothromboxane B2, a 11-dehydrothromboxane B2 competitive product, a chromogenic substrate, a stop buffer and a 11-dehydrothromboxane B2 standard solution, wherein the monoclonal antibody of 11-dehydrothromboxane B2 is a mouse monoclonal antibody, the sequence of a light chain variable region of the mouse monoclonal antibody is as shown in SEQ ID NO.2 in a sequence table, and the sequence of a heavy chain variable region of the mouse monoclonal antibody is as shown in SEQ ID NO.4 in the sequence table. The enzyme-linked immunosorbent assay kit and the method thereof have the characteristics of accuracy, high sensitivity and the like for detecting aspirin metabolism so as to judge whether a patient has aspirin drug resistance or resistance, and are not easily influenced by biochemical indexes such as creatinine and the like; and the problem of failure or poor effect of anti-platelet aggregation treatment caused by aspirin resistance of clinical patients can be greatly reduced.

The invention discloses an aspirin resistance relevant GPIa gene polymorphic site and application. Antiplatelet drugs (especially aspirin) have great significance in treatment of ischemic stroke, but the current survey result shows that many patients in ischemic stroke relapse into the stroke even after taking the antiplatelet drugs, and the phenomenon is called as antiplatelet drug resistance. The applicant determines the aspirin resistance relevant GPIa gene polymorphic site GPIa(C807T), and designs a primer for detecting the polymorphism of the site for the site, the primer can be used for preparing a kit for screening out aspirin resistance patients so as to select antiplatelet drugs for patients of ischemic stroke, and the aspirin resistance and stroke relapse rate are decreased.

The invention discloses a chemiluminiscence detection method and a chemiluminiscence detection kit for aspirin metabolism and platelet high reactivity. The kit comprises a monoclonal antibody combinedwith 11-dehydrothromboxane B2, a competitive product of 11-dehydrothromboxane B2, magnetic particles and a luminous substrate, wherein the monoclonal antibody is a mouse monoclonal antibody, the amino acid sequence of a light chain variable region of the mouse monoclonal antibody is shown as SEQ ID NO: 2 in a sequence table, and the amino acid sequence of a heavy chain variable region of the mouse monoclonal antibody is shown as SEQ ID NO: 4 in the sequence table. According to the present invention, with the application of the aspirin metabolism and platelet high-reactivity chemiluminiscencedetection method and the detection kit, whether the patient has aspirin drug resistance or resistance can be rapidly detected; the kit and the detection method provided by the invention have the advantages that the sensitivity is high, the accuracy is good, the kit and the detection method are not easily influenced by biochemical indexes, and the problem that the anti-platelet aggregation treatment of a clinical patient fails or the effect is poor due to aspirin resistance is solved.

The present invention provides the new use of a kind of medicine composition. The medicine composition consists of red sage, safflower, sodium chloride for injection, etc. Clinical test shows that the medicine composition has the property of improving aspirin resistance and may be used in treating aspirin resistance cardiac vascular diseases to raise the life quality of the aspirin resistance cardiac vascular disease patient.

The invention relates to the application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance, wherein pharmaceutical composition comprises (by weight ratio) root of red rooted saliva 50-60 parts, notoginseng 16-20 parts, borneol 0.1-3 parts, the composition can be prepared into any of the pharmacologically acceptable dose form.

A Chinese medicine for treating the aspirin-resistant cardiovascular disease is prepared from 14 Chinese-medicinal materials including astragalus root, Chinese angelica root, rehmannia root, peach kernel, etc.

The present invention provides the new use of a kind of medicine composition. The medicine composition consists of red sage, red peony root, prepared fleeceflower root, wolfberry fruit, kudzu vine root and other Chinese medicinal materials. Clinical test shows that the medicine composition has the property of improving aspirin resistance and may be used in treating aspirin resistance cardiac vascular diseases to raise the life quality of the aspirin resistance cardiac vascular disease patient.

A Chinese medicine for treating the aspirin-resistant cardiovascular disease is prepared from 12 Chinese-medicinal materials including red sage root, Chuanxiong rhizome, red peony root, safflower, etc.

The present invention provides the new use of a kind of medicine composition. The medicine composition consists of notoginseng, rose rhodobryun herb, fleabane, red sage, prepared fleeceflower root, etc. Clinical test shows that the medicine composition has the property of improving aspirin resistance and may be used in treating aspirin resistance cardiac vascular diseases to raise the life quality of the aspirin resistance cardiac vascular disease patient.